
|Articles|October 2, 2006
New warnings released for colorectal cancer drug
Rare cases of a brain-capillary leak syndrome called reversible posterior leukoencephalopathy syndrome have led to a revision in the Warnings and Adverse Reactions sections of the prescribing information for bevacizumab (Avastin, Genentech).
Advertisement
Rare cases of a brain-capillary leak syndrome called reversible posterior leukoencephalopathy syndrome have led to a revision in the Warnings and Adverse Reactions sections of the prescribing information for bevacizumab (Avastin, Genentech). The effect occurred at a rate of
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
2
FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies
3
FDA Approves Stelara for Pediatric Ulcerative Colitis
4
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
5




























